AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02711241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: 1 gram by slow IV infusion
Study NCT02711241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: 80 mg by slow intravenous infusion
Study NCT00883519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: 12 psychotherapy sessions delivered over 16 weeks
Study NCT03988907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
Study NCT03988907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single dose administration of 2 mg midazolam
Study NCT02810964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane Nutraceutical
Description: Sulforaphane Nutraceutical 6 tablets by mouth daily
Study NCT02810964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical-appearing Placebo
Description: Identical-appearing Placebo 6 tablets by mouth daily
Study NCT01052025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
Study NCT00715988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone HCl Inject 10 mg/ml (will require dilution)
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
Study NCT00715988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
Study NCT02273583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous oral cyclophosphamide and methotrexate
Study NCT02277717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985 (trastuzumab vc-seco-DUBA)
Description: IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study NCT01641939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.
Study NCT01641939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
Study NCT01641939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: trastuzumab emtansine 2.4 mg/kg IV once a week
Study NCT00883519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents and Parents
Description: 12 psychotherapy sessions delivered over 16 weeks
Study NCT01410344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine and Busulfan
Description: RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.
Study NCT01410344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine and Melphalan
Description: RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
Study NCT01410344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan and Fludarabine
Description: MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.
Study NCT01410344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide and Total Body Irradiation
Description: MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.
Study NCT02122913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
Study NCT00794898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Description: Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
Study NCT04086498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The group received a plan for a isocaloric Mediterranean Diet
Study NCT04086498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KEMEPHY
Description: The group received a plan for a ketogenic mediterranean with herbal extracts diet
Study NCT04086498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KD
Description: The group received a plan for a low carbohydrate ketogenic diet
Study NCT05037578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Grace
Description: A multilevel church-based intervention to encourage cognitive screens and brain health.
Study NCT05037578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Grace
Description: A multilevel church-based intervention to encourage cognitive screens and brain health.
Study NCT02635932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Day Splint
Description: A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
Study NCT03228160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linearly Polarized Near-Infrared light Irradiation
Description: The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
Study NCT03228160 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Linearly Polarized Near-Infrared light Irradiation
Description: The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
Study NCT02635932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Night Splint
Description: A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
Study NCT02782858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose
Study NCT02782858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly IV repeated dose
Study NCT02856152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 capsule
Description: Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
Study NCT04714515 — intervention group
Intervention type: DRUG
Intervention: Montelukast
Description: An FDA approved medicine to treat asthmatic patients
Study NCT04714515 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: An FDA approved antiarthritis drug
Study NCT04714515 — intervention group
Intervention type: DRUG
Intervention: Ivermectin
Description: An FDA approved anti-parasitic medicine
Study NCT00883714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
Study NCT00883714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Instruction
Description: The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
Study NCT02535182 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells.
Study NCT04257994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: obtaining a buccal smear sample
Description: A sample will be taken from the inside of the participants' cheeks using a soft brush
Study NCT02167178 — intervention group
Intervention type: OTHER
Intervention: Administration of 0.9% NaCl solution
Description: Volunteers administered 0.9% NaCl solution in 250ml boluses
Study NCT02167178 — intervention group
Intervention type: OTHER
Intervention: Measurement of stroke volume
Description: The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
Study NCT02856152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 tablets
Description: Three 90 mg GDC-0276 tablets administered orally.
Study NCT02167178 — intervention group
Intervention type: OTHER
Intervention: Measurement of microvascular blood flow
Description: Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
Study NCT02167178 — intervention group
Intervention type: OTHER
Intervention: Administration of gelofusine
Description: Volunteers administered gelofusine in 250ml boluses
Study NCT00679952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drainage of pancreatic duct
Description: A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
Study NCT00679952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural drainage of pancreatic duct
Description: Natural drainage group
Study NCT03280004 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin Hydrochloride and Sodium Chloride Injection
Description: Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
Study NCT05402644 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy
Description: Liver resection
Study NCT02160392 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
Study NCT02669472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: Intervention sites received regularly-scheduled, discount, fresh F\&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
Study NCT02669472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F\&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F\&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
Study NCT02669472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
Study NCT02007603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Amoxicillin / clavulanic acid
Description: Patients receive amoxicillin / clavulanic acid due to clinical necessity
Study NCT02007603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin / sulbactam
Description: Patients receive ampicillin / sulbactam due to clinical necessity
Study NCT02007603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blooddraws for pharmacokinetic profiling
Description: Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
Study NCT04244929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using standard anterior approach.
Study NCT03480724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Google Cardboard VRA
Description: Intervention was randomized and shuffled.
Study NCT04244929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using standard anterior approach.
Study NCT04244929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining
Description: Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
Study NCT04244929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice
Description: Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: VKA: Warfarin (Waran)
Description: VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: NOAC: Rivaroxaban (Xarelto, BAY59-7939)
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: NOAC: Dabigatran etexilate
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: NOAC: Apixaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: NOAC: Edoxaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02611635 — intervention group
Intervention type: DRUG
Intervention: NOAC: Lixiana
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT01815229 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tracheal lavages
Description: tracheal lavages obtained during endotracheal intubation.
Study NCT01815229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheal lavages
Description: tracheal lavages obtained during endotracheal intubation.